

文章编号:1001-6880(2016)10-1562-06

球毛壳菌 CIB-160 次生代谢产物的分离鉴定及其免疫活性

徐国波^{1,2}, 刘俊¹, 肖耀华¹, 周孟¹, 杨涛², 李国友^{2*}¹贵州医科大学药学院, 贵阳 550004; ²中国科学院成都生物研究所微生物重点实验室, 成都 610041

摘要:采用硅胶柱层析、HPLC、Sephadex LH-20 凝胶柱层析等分离方法对球毛壳菌 CIB-160 的次生代谢产物进行纯化, 得到 10 个化合物。通过 NMR、HR-MS 和旋光数据分析以及文献比对, 其结构鉴定为 chaetoglobosins A (1)、C (2)、E (3)、F (5)、F_{ex} (6)、W (7), penochalasin F (4), 5-(methyl-2-but enyl)-indole-2,3-dione (8)、chaetoviridin A (9) 和 cochl iodone A (10)。**8** 和 **10** 为首次从野生型球毛壳菌代谢物中分离得到的化合物。体外免疫活性检测显示 **1~6** 对小鼠脾细胞的增殖具有抑制作用, IC₅₀ 值分别为 0.21、2.8、2.3、2.2、1.7、2.7 μM。同时 **1~6** 具有较强的细胞毒性, 对静息小鼠脾细胞存活率 IC₅₀ 值分别 0.82、7.5、2.3、6.1、4.6、6.7 μM。

关键词:球毛壳菌; 次生代谢产物; 分离纯化; 免疫活性

中图分类号:O629.9

文献标识码:A

DOI:10.16333/j.1001-6880.2016.10.011

Isolation and Identification of Secondary Metabolites from *Chaetomium globosum* CIB-160 and Their Immunological Activity

XU Guo-bo^{1,2}, LIU Jun¹, XIAO Yao-hua¹, ZHOU Meng¹, YANG Tao², LI Guo-you^{2*}¹School of Pharmacy, Guizhou Medical University, Guiyang 550004, China; ²Key Laboratory of

Environmental and Applied Microbiology, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China

Abstract: Ten compounds were isolated and purified from the metabolites of *Chaetomium globosum* CIB-160 by silica gel column chromatography, HPLC, Sephadex LH-20 chromatography. Their chemical structures were identified as chaetoglobosins A (**1**)、C (**2**)、E (**3**)、F (**5**)、F_{ex} (**6**)、W (**7**)、penochalasin F (**4**)、5-(methyl-2-but enyl)-indole-2,3-dione (**8**)、chaetoviridin A (**9**)、and cochl iodone A (**10**) on the basis of NMR, HR-MS and optical rotation data, compound **8** and **10** were first reported from wild strain of *C. globosum*. Compounds **1~6** showed significant inhibition of mouse spleen cell proliferation, their IC₅₀ values were 0.21, 2.8, 2.3, 2.2, 1.7, 2.7 μM, respectively. The IC₅₀ values of mice spleen cell survival rates successively were 0.82, 7.5, 2.3, 6.1, 4.6, 6.7 μM, which indicated compounds **1~6** possessed strong cytotoxicity.

Key words: *Chaetomium globosum*; secondary metabolites; isolation and purification; immunological activity

球毛壳菌(*Chaetomium globosum*)常见于土壤和空气中, 是毛壳属(*Chaetomium*)中研究最多的菌种, 其代谢物中以细胞松弛素类型的化合物居多, 包括 chaetoglobosins A-G、J、Q、R、T、U、V、W、F_{ex}、penochalasin A、cytoglobosins A-G、isochaetoglobosin D。球毛壳菌代谢产物因具有广泛的生物活性如抗肿瘤、抗疟疾、抗菌、免疫调节等而引起药物学家和生物学家的重视^[1]。前期研究中, 本课题组从毛壳属菌株发现多个具有抗肿瘤^[2]、抗菌^[3]、抗氧化^[4]、调节植物生长^[5]等生物活性的新型化合物。为了从毛壳属菌种中寻找更多的活性物质, 课题组对毛壳

属菌种进行系统研究。尽管文献报道球毛壳菌次级代谢产物研究较多, 但基于菌株来源不同, 其代谢产物会有较大的差异。本文对从雅安土壤中分离得到的一株球毛壳菌进行了研究, 从其次生代谢产物中分离得到了化合物 chaetoglobosins A (**1**)、C (**2**)、E (**3**)、F (**5**)、F_{ex} (**6**)、W (**7**)、penochalasin F (**4**)、5-(methyl-2-but enyl)-indole-2,3-dione (**8**)、chaetoviridin A (**9**) 和 cochl iodone A (**10**)。其中 **8** 和 **10** 为首次从野生型球毛壳菌代谢物中分离得到的化合物。免疫活性实验测试结果显示化合物 **1~6** 细胞松弛素类化合物显示较强的抑制活性。

1 仪器与材料

1.1 材料

菌种球毛壳(*Chaetomium globosum* CIB-160)是

收稿日期:2016-06-01 接受日期:2016-07-15

基金项目:国家自然科学基金(21272228)

*通讯作者 Tel:86-28-82890415; E-mail: lgy@ cib.ac.cn




图 1 化合物 1~10 的化学结构

Fig. 1 Chemical structures of compounds 1-10

从四川省雅安土壤中采集分离得到,由中国科学院成都生物研究所杨涛副研究员鉴定,以 PDA 斜面培养基 4 ℃ 转种保存于冰箱中。菌种保藏于中国科学院成都生物研究所。

液体培养基: 20% 马铃薯提取物, 2% 葡萄糖, 0.35 KH₂PO₄, 0.15% MgSO₄ · 7H₂O, 0.15% 酵母膏, 用 40% NaOH 水溶液将 pH 调至中性。**固体培养基:** 大米中加入 0.3% 的蛋白胨混合均匀。

Bal b/c 小鼠 [四川大学动物实验中心, SCXK (川)2013-026]。

1.2 主要仪器与试剂

Bruker Bio TOF IIIQ 质谱仪(美国 Bruker Daltonic 公司), 核磁共振波谱仪 Bruker Avance 600(德国 Bruker 公司), 红外光谱仪 Perkin Elmer spectrum one FT-IR(美国 Perkin Elmer 公司), 旋光仪 Perkin Elmer 341(美国 Perkin Elmer 公司), 半制备 HPLC 仪器(上海伍丰有限公司); 硅胶 H(300~400 和 200~300 目, 青岛海洋化工厂), 薄层色谱使用硅胶 GF₂₅₄(青岛海洋化工); 分析级石油醚(60~90 ℃)、乙酸乙酯、氯仿、甲醇(国药集团化学试剂有限公司), 色谱甲醇(美国 Thermo Fisher 公司), 气代甲醇、气代氯仿、气代丙酮(瑞士 ARMAR 公司), RPMI 1640 完全培养基(上海宝曼生物科技有限公司), CFSE(美国 Invitrogen Molecular Probes 公司), 流式细胞仪(美国 Becton Dickison 公司), Anti-CD3/CD28(上海沪震有限公司), CCK-8(日本 Dojindo 研究所)。

2 实验方法

2.1 发酵

一级种子的发酵: 在无菌室中将斜面上的菌种接种到已灭菌的液体培养基中, 于恒温箱中培养 3 d。**二级发酵:** 将一级的种子按 10% 的接种量均匀地接种到已灭菌的固体培养基上, 并将其放在培养箱中 28 ℃ 恒温培养 25 d。

2.2 提取与分离

室温下用乙酸乙酯(10 L × 3, 一次 2 d)浸提球毛壳霉菌固态发酵物(10.0 kg), 提取液减压浓缩得浸膏(67.0 g)。总浸膏经硅胶柱层析(500 g, Φ 60 mm × 500 mm, 石油醚-丙酮 5:1, 2:1, 1:1, 0:1, 各 3500 mL), 分为四个部分 A(46.4 g)、B(7.2 g)、C(4.8 g) 和 D(5.5 g)。A 部分为大量的油脂类以及麦角固醇类物质。B 用硅胶柱进一步分离(200 g, 300~400 目, Φ 50 mm × 350 mm), 以石油醚-丙酮(3:1, 800 mL)洗脱得到混合物 B1 和 B2。B1 经 HPLC(45%, 乙腈-水)分离得到化合物 9(10.0 mg) 和 10(25.0 mg)。B2 经 Sephadex LH20 柱层析(氯仿:甲醇, 1:1)得到化合物 8(5.0 mg)。C 部分粗提取物经与对照品对照为嘧啶类化合物。D 部分经 HPLC(45%, 乙腈-水)分离得到化合物 4(3.0 mg)、7(3.4 mg) 以及混合物 D1 和 D2。D1 经 HPLC(40%, 乙腈-水)分离得到化合物 1(60.0 mg)、2(40.0 mg) 和 5(6.0 mg)。D2 经 HPLC(41%, 甲醇-水)分离得到化合物 3(35.0 mg) 和 6(2.5 mg)。

2.3 体外免疫活性实验

体外免疫活性实验参考文献方法^[6], 即刺激后脾细胞增殖检测: 取 Bal b/c 小鼠(6~8 w)脾脏, 制

备单细胞悬液, 细胞密度调整为 1×10^6 个/mL。使用 $2 \mu\text{mol/L}$ 羧基荧光素乙酰乙酸琥珀酰亚胺酯 (CFSE) 于 37°C 避光染色细胞 10 min , 加入冰冷的 RPMI 1640 完全培养基终止染色。使用 2 mg/L anti-CD3/ 1 mg/L anti-CD28 刺激脾细胞 (1×10^6 个/mL)。加入不同浓度筛选药物后, 于 $37^\circ\text{C}, 5\% \text{ CO}_2$ 中培养 96 h , 并以 BD750 为阳性对照^[6]。流式细胞仪检测细胞增殖。

静息脾细胞活力检测: 取 Bal b/c 小鼠 ($6 \sim 8\text{ w}$) 脾脏, 制备单细胞悬液, 细胞密度调整为 1×10^6 个/mL。加入不同浓度筛选药物后, 于 $37^\circ\text{C}, 5\% \text{ CO}_2$ 中培养 48 h 。使用 CCK-8 检测细胞活力, 具体操作参照 CCK-8 检测试剂盒说明书。

3 结果与分析

3.1 发酵产物的鉴定

Chaetoglobosin A (1) 黄色粉末; HR-ESI-MS (positive mode) m/z 551.2512 [$\text{M} + \text{Na}$]⁺ (calcd for $\text{C}_{32}\text{H}_{36}\text{N}_2\text{O}_5\text{Na}^+$, 551.2524); ^1H NMR (600 MHz, pyridine- d_5): δ 11.90 (1H, s, NH-1'), 9.42 (1H, s, NH-2), 8.04 (1H, d, $J = 6.5\text{ Hz}$, H-22), 7.87 (1H, d, $J = 6.0\text{ Hz}$, H-4'), 7.58 (1H, overlap, H-7'), 7.33 (1H, s, H-2'), 7.26 (2H, overlap, H-5', H-6'), 7.06 (1H, d, $J = 6.5\text{ Hz}$, H-21), 6.63 (1H, dd, $J = 15.0, 6.0\text{ Hz}$, H-13), 5.61 (1H, d, $J = 9.4\text{ Hz}$, H-17), 5.44 (1H, s, H-19), 5.29 (1H, m, H-14), 4.15 (1H, s, H-3), 3.29 (1H, s, H-4), 3.13 (2H, overlap, H-8, H-10), 3.05 (1H, dd, $J = 14.3, 6.6\text{ Hz}$, H-10), 2.63 (1H, dd, $J = 9.6, 4.9\text{ Hz}$, H-7), 2.41 (1H, m, H-16), 2.17 (1H, d like, H-15), 2.06 (1H, m, H-5), 1.93 (1H, m, H-15), 1.54 (3H, s, CH_3 -18), 1.28 (3H, d, $J = 8.1\text{ Hz}$, CH_3 -12), 1.08 (3H, d, $J = 7.2\text{ Hz}$, CH_3 -11), 0.86 (3H, d, $J = 6.6\text{ Hz}$, CH_3 -16); ^{13}C NMR (150 MHz, acetone- d_6): δ 201.0 (C-20), 197.8 (C-23), 172.8 (C-1), 138.9 (C-17), 136.7 (C-1'a), 135.7 (C-21), 132.7 (C-22), 132.6 (C-14), 132.2 (C-18), 128.9 (C-13), 127.8 (C-3'a), 124.2 (C-5'), 121.2 (C-2'), 118.9 (C-6'), 118.5 (C-4'), 111.4 (C-7'), 109.7 (C-3'), 63.2 (C-9), 62.0 (C-7), 57.2 (C-6), 52.2 (C-3), 48.3 (C-8), 46.7 (C-4), 41.3 (C-15), 36.4 (C-5), 33.2 (C-10), 32.0 (C-16), 20.4 ($\text{CH}_3\text{-C}_{16}$), 12.3 ($\text{CH}_3\text{-11}$), 9.8 ($\text{CH}_3\text{-C}_{18}$)。与文献中 chaetoglobosin A 的相关数据一致^{[7][8]}。

Chaetoglobosin C (2) 白色粉末; HR-ESI-MS (positive mode) m/z 551.2524 [$\text{M} + \text{Na}$]⁺ (calcd for $\text{C}_{32}\text{H}_{36}\text{N}_2\text{O}_5\text{Na}^+$, 551.2524); ^1H NMR (600 MHz, DMSO- d_6): δ 10.92 (1H, s, NH-1'), 8.43 (1H, s, NH-2), 7.53 (1H, d, $J = 8.1\text{ Hz}$, H-4'), 7.31 (1H, d, $J = 8.1\text{ Hz}$, H-7'), 7.12 (1H, s, H-2'), 7.05 (1H, t, $J = 8.1\text{ Hz}$, H-6'), 6.99 (1H, t, $J = 8.1\text{ Hz}$, H-5'), 6.06 (1H, dd, $J = 14.4, 6.0\text{ Hz}$, H-13), 5.88 (1H, d, $J = 9.8\text{ Hz}$, H-17), 4.94 (1H, t, $J = 11.9\text{ Hz}$, H-14), 3.74 (1H, s, H-3), 2.83 (1H, dd, $J = 14.5, 5.5\text{ Hz}$, H-10), 2.73 (1H, dd, $J = 14.5, 3.4\text{ Hz}$, H-10), 2.63 (1H, d, $J = 6.0\text{ Hz}$, H-8), 2.45 (1H, m, H-4), 2.28 (1H, overlap, H-7 或 H-16), 2.24 (1H, m, H-7 或 H-16), 2.13 (1H, dd, $J = 9.9, 6.0\text{ Hz}$, H-15), 1.80 (1H, m, H-5 或 H-15), 1.73 (1H, overlap, H-5 或 H-15), 1.68 (3H, s, CH_3 -18), 1.15 (3H, s, CH_3 -12), 0.93 (3H, d, $J = 6.7\text{ Hz}$, CH_3 -11), 0.91 (3H, d, $J = 7.2\text{ Hz}$, CH_3 -16); ^{13}C NMR (150 MHz, DMSO- d_6): δ 208.2 (C-19), 205.3 (C-20), 196.2 (C-23), 173.9 (C-1), 155.8 (C-17), 135.9 (C-1'a), 131.0 (C-18), 128.2 (C-3'a), 127.1 (C-13), 125.2 (C-5'), 121.0 (C-2'), 118.7 (C-6'), 118.4 (C-4'), 111.3 (C-7'), 108.1 (C-3'), 62.3 (C-9), 60.4 (C-7), 56.7 (C-6), 52.3 (C-3), 48.5 (C-4), 48.3 (C-8), 39.6 (C-15), 37.1 (C-22), 36.2 (C-5), 32.6 (C-16), 32.0 (C-10), 31.8 (C-21), 19.4 ($\text{CH}_3\text{-C}_{16}$), 19.1 (C-12), 12.4 (C-11), 10.0 ($\text{CH}_3\text{-C}_{18}$)。与文献中 chaetoglobosin C 的相关数据一致^[7]。

Chaetoglobosin E (3) 白色粉末; HR-ESI-MS (positive mode) m/z 553.2679 [$\text{M} + \text{Na}$]⁺ (calcd for $\text{C}_{32}\text{H}_{38}\text{N}_2\text{O}_5\text{Na}^+$, 553.2674); ^1H NMR (600 MHz, pyridine- d_5): δ 11.90 (1H, s, NH-1'), 9.24 (1H, s, NH-2), 7.85 (1H, d, $J = 7.8\text{ Hz}$, H-4'), 7.68 (1H, overlap, H-7'), 7.32 (2H, m, H-2' 和 H-6'), 7.27 (1H, t, $J = 7.8\text{ Hz}$, H-5'), 7.05 (1H, dd, $J = 15.3, 7.0\text{ Hz}$, H-13), 6.36 (1H, d, $J = 9.1\text{ Hz}$, H-17), 5.50 (1H, t like, H-14), 5.33 (1H, t, $J = 7.8\text{ Hz}$, H-20), 4.60 (1H, d, $J = 9.3\text{ Hz}$, H-8), 4.00 (1H, t, $J = 7.3\text{ Hz}$, H-3), 3.46 (1H, overlap, H-4), 3.43 (1H, overlap, H-22), 3.13 (1H, dd, $J = 14.1, 7.4\text{ Hz}$, H-10), 3.02 (1H, dd, $J = 14.1, 7.4\text{ Hz}$, H-10), 2.72 (1H, t like, H-7), 2.62 (1H, m, H-16), 2.45 (2H, overlap, H-15, H-21), 2.25 (1H, d, $J = 13.2\text{ Hz}$, H-15), 1.96 (3H, s, CH_3 -18), 1.92 (3H, s, CH_3 -12), 1.51 (3H,

$\text{s}, \text{CH}_3\text{-}11), 0.84 (3\text{H}, \text{d}, J = 6.6 \text{ Hz}, \text{CH}_3\text{-}16); ^{13}\text{C}$ NMR (150 MHz, pyridine- d_5): δ 210.7 (C-19), 204.8 (C-23), 175.3 (C-1), 148.4 (C-17), 137.5 (C-1'a), 135.4 (C-18), 134.2 (C-14), 134.2 (C-6), 130.0 (C-13), 128.0 (C-3'a), 126.3 (C-5), 124.3 (C-5'), 121.7 (C-2'), 119.2 (C-6'), 118.7 (C-4'), 112.0 (C-7'), 111.3 (C-3'), 71.7 (C-20), 68.8 (C-7), 62.7 (C-9), 58.2 (C-4), 52.6 (C-3), 50.6 (C-8), 41.1 (C-15), 33.3 (C-21), 33.3 (C-10), 32.0 (C-16), 19.6 ($\text{CH}_3\text{-C}_{16}$), 17.3 (C-12), 14.9 (C-11), 12.2 ($\text{CH}_3\text{-C}_{18}$)。与文献中 chaetoglobosin E 的相关数据一致^[7]。

Penochalasin F (4) 白色粉末; HR-ESI-MS (positive mode) m/z 553.2676 [$\text{M} + \text{Na}$]⁺ (calcd for $\text{C}_{32}\text{H}_{38}\text{N}_2\text{O}_5\text{Na}^+$, 553.2674); ¹H NMR (600 MHz, pyridine- d_5): δ 12.08 (1 H, s, NH-1'), 9.39 (1 H, s, NH-2), 7.90 (1 H, d, $J = 7.6 \text{ Hz}$, H-4'), 7.66 (1 H, d, $J = 7.8 \text{ Hz}$, H-7'), 7.38 (1 H, d, $J = 2.1 \text{ Hz}$, H-2'), 7.31 ~ 7.25 (2 H, overlap, H-5', H-6'), 6.68 (1 H, dd, $J = 14.3, 10.4 \text{ Hz}$, H-13), 5.47 (1 H, d, $J = 8.9 \text{ Hz}$, H-17), 5.32 (1 H, m, H-14), 4.18 (1 H, s, H-19), 3.50 (1 H, m, H-3), 3.20 (1 H, dd, $J = 14.4, 5.3 \text{ Hz}$, H-10), 3.15 (1 H, d, $J = 5.5 \text{ Hz}$, H-7), 3.08 (1 H, dd, $J = 14.3, 5.6 \text{ Hz}$, H-10), 2.90 (1 H, d, $J = 3.7 \text{ Hz}$, H-4), 2.78 ~ 2.67 (3 H, overlap, H-22, H-16 或 H-21), 2.45 ~ 2.39 (2 H, overlap, H-5, H-16 或 H-21), 2.16 (1 H, d like, H-15), 2.10 (1 H, q like, H-22), 1.86 (1 H, dt, $J = 13.5, 11.0 \text{ Hz}$, H-15), 1.59 (3 H, s, $\text{CH}_3\text{-}18$), 1.31 (3 H, s, H-12), 1.10 (3 H, d, $J = 7.2 \text{ Hz}$, H-11), 0.86 (3 H, d, $J = 6.6 \text{ Hz}$, $\text{CH}_3\text{-}16$); ¹³C NMR (150 MHz, pyridine- d_5): δ 210.8 (C-20), 209.2 (C-23), 174.8 (C-1), 138.2 (C-17), 137.3 (C-1'a), 133.4 (C-14), 132.5 (C-18), 129.4 (C-13), 128.4 (C-3'a), 125.2 (C-2'), 121.7 (C-6'), 119.4 (C-5'), 118.9 (C-4'), 112.1 (C-7'), 109.9 (C-3'), 83.1 (C-19), 64.6 (C-9), 62.1 (C-7), 57.1 (C-6), 53.1 (C-3), 49.6 (C-8), 49.3 (C-4), 41.5 (C-15), 37.0 (C-5), 36.2 (C-22), 34.6 (C-21), 34.0 (C-16), 32.1 (C-10), 21.0 ($\text{CH}_3\text{-C}_{16}$), 19.5 (C-12), 12.7 (C-11), 10.9 ($\text{CH}_3\text{-C}_{18}$)。与文献中 penochalasin F 的相关数据一致^[9]。

Chaetoglobosin F (5) 白色粉末; HR-ESI-MS (positive mode) m/z 553.2871 [$\text{M} + \text{Na}$]⁺ (calcd for $\text{C}_{32}\text{H}_{38}\text{N}_2\text{O}_5\text{Na}^+$, 553.2674); ¹H NMR (600 MHz, ac-

etone- d_6): δ 10.08 (1 H, s, NH-1'), 7.55 (1 H, d, $J = 7.9 \text{ Hz}$, H-4'), 7.38 (1 H, d, $J = 8.0 \text{ Hz}$, H-7'), 7.30 (1 H, s), 7.15 (1 H, s), 7.09 (1 H, t, $J = 7.5 \text{ Hz}$, H-6'), 7.02 (1 H, t, $J = 7.5 \text{ Hz}$, H-5'), 6.45 (1 H, dd, $J = 15.1, 9.8 \text{ Hz}$, H-13), 6.32 (1 H, d, $J = 9.5 \text{ Hz}$, H-17), 5.27 (1 H, m, H-14), 4.73 (1 H, m, H-19), 3.85 (1 H, t like, H-3), 3.79 (1 H, d, $J = 7.2 \text{ Hz}$, H-10), 3.31 (1 H, overlap, H-8), 3.02 (1 H, s, H-4), 2.89 (1 H, dd, $J = 14.1, 5.6 \text{ Hz}$, H-10), 2.66 (1 H, d, $J = 6.0 \text{ Hz}$, H-22), 2.62 (1 H, d, $J = 5.1 \text{ Hz}$, H-7), 2.43 (1 H, m, H-15 或 H-16), 2.37 (1 H, m, H-16 或 H-15), 2.24 (1 H, dd, $J = 9.7, 5.7 \text{ Hz}$, H-15), 1.80 (3 H, s, $\text{CH}_3\text{-}18$), 1.75 ~ 1.62 (3 H, overlap, H-21, H-22), 1.16 (3 H, s, H-12), 1.07 (3 H, d, $J = 6.7 \text{ Hz}$, H-11), 0.81 (3 H, d, $J = 7.3 \text{ Hz}$, $\text{CH}_3\text{-}16$); ¹³C NMR (150 MHz, acetone- d_6): δ 210.2 (C-19), 205.5 (C-23), 175.5 (C-1), 150.1 (C-17), 138.2 (C-1'a), 136.2 (C-18), 134.4 (C-14), 130.8 (C-13), 129.3 (C-3'a), 125.5 (C-5'), 122.8 (C-2'), 120.3 (C-6'), 119.8 (C-4'), 112.9 (C-7'), 111.6 (C-3'), 72.6 (C-20), 65.7 (C-9), 63.1 (C-7), 58.2 (C-6), 54.0 (C-3), 50.3 (C-8), 49.4 (C-4), 42.2 (C-15), 38.6 (C-22), 38.0 (C-5), 35.0 (C-16), 34.8 (C-21), 32.6 (C-10), 20.7 ($\text{CH}_3\text{-C}_{16}$), 20.2 (C-12), 13.4 (C-11), 9.8 ($\text{CH}_3\text{-C}_{18}$)。与文献中 chaetoglobosin F 的相关数据一致^[7]。

Chaetoglobosin F_{ex} (6) 白色粉末; $[\alpha]_{\text{D}}^{20} = +62^\circ$ ($c 0.1$, MeOH); HR-ESI-MS (positive mode) m/z 553.2674 [$\text{M} + \text{Na}$]⁺ (calcd for $\text{C}_{32}\text{H}_{38}\text{N}_2\text{O}_5\text{Na}^+$, 553.2674); ¹H NMR (600 MHz, acetone- d_6): δ 10.12 (1 H, s, NH-1'), 7.53 (1 H, d, $J = 7.9 \text{ Hz}$, H-4'), 7.37 (1 H, d, $J = 8.0 \text{ Hz}$, H-7'), 7.19-7.13 (2 H, overlap, H-2', NH-2), 7.08 (1 H, t, $J = 7.2 \text{ Hz}$, H-6'), 7.01 (1 H, t, $J = 7.1 \text{ Hz}$, H-5'), 6.26 (1 H, d, $J = 9.5 \text{ Hz}$, H-13), 6.22 (1 H, m, H-17), 5.23 (1 H, m, H-14), 5.20 (1 H, s, H-12), 4.96 (1 H, s, H-12), 4.70 (1 H, brs, H-20), 3.86 (2 H, overlap, H-7, H-22), 3.45 (1 H, m, H-3), 2.87 ~ 2.81 (3 H, H-10, H-22, H-21), 2.78 (1 H, overlap, H-5 或 H-4), 2.74 ~ 2.69 (2 H, H-21, H-4 或 H-5), 2.65 ~ 2.57 (2 H, overlap, H-15, H-10 或 H-22), 2.37 (1 H, m, H-10 或 H-22), 2.28 ~ 2.19 (1 H, m, H-8), 1.79 (3 H, s, $\text{CH}_3\text{-}18$), 1.69 ~ 1.62 (1 H, m, H-15), 1.02 (3 H, d, $J = 6.7 \text{ Hz}$, H-11), 0.88 (3 H, d, $J = 7.3 \text{ Hz}$,

$\text{CH}_3\text{-}16$; ^{13}C NMR (150 MHz, acetone- d_6): δ 208.7 (C-23), 204.0 (C-19), 173.9 (C-1), 150.6 (C-6), 148.7 (C-17), 136.7 (C-1'a), 134.7 (C-14), 133.7 (C-18), 129.0 (C-3'a), 127.9 (C-13), 124.2 (C-2'), 121.3 (C-6'), 118.8 (C-5'), 118.3 (C-4'), 112.0 (C-12), 111.5 (C-7'), 110.1 (C-3'), 71.1 (C-20), 70.3 (C-7), 62.6 (C-9), 52.3 (C-3), 49.2 (C-8), 47.2 (C-4), 40.9 (C-15), 37.0 (C-22), 33.3 (C-10), 32.7 (C-16), 31.9 (C-21), 31.2 (C-5), 19.3 (C-C₁₆), 13.0 (C-11), 11.5 (C-C₁₈)。与文献中 chaetoglobosin F_{ex} 的相关数据一致^[10]。

Chaetoglobosin W (7) 白色粉末; HR-ESI-MS (positive mode) m/z 569.2626 [$\text{M} + \text{Na}$]⁺ (calcd for C₃₂H₃₈N₂O₆Na⁺, 569.2626); ^1H NMR (600 MHz, pyridine- d_5): δ 11.94 (1H, s, NH-1'), 9.87 (1H, s, NH-2), 7.99 (1H, dd, $J = 8.9, 3.0$ Hz, H-4'), 7.61 (1H, s, H-2'), 7.54 (1H, dd, $J = 6.0, 3.0$ Hz, H-7'), 7.27 (2H, overlap, H-5', H-6'), 6.68 (1H, m, H-13), 6.45 (1H, d, $J = 9.8$ Hz, H-17), 6.28 (1H, m, H-14), 5.63 (1H, t like, H-20), 5.32 (1H, t like, H-7), 3.99 (1H, m, H-16), 3.78 (1H, d, $J = 15.2$ Hz, H-10), 3.53 (1H, d, $J = 15.0$ Hz, H-10), 3.45 (1H, s, H-4), 3.19 (1H, m, H-8 或 H-15), 2.99 (2H, overlap, H-22, H-8 或 H-15), 2.67 (1H, m, H-22), 2.52 (1H, m, H-21 或 H-5), 2.25 (2H, overlap, H-21 或 H-5), 2.14 (1H, m, H-15), 1.90 (3H, s, CH₃-18), 1.69 (3H, s, CH₃-12), 1.29 (3H, d, $J = 7.2$ Hz, CH₃-11), 0.81 (3H, d, $J = 6.7$ Hz, CH₃-16); ^{13}C NMR (150 MHz, pyridine- d_5): δ 208.2 (C-23), 205.9 (C-19), 175.3 (C-1), 149.7 (C-17), 138.2 (C-1'a), 134.8 (C-14), 132.5 (C-13), 130.0 (C-3'a), 126.1 (C-2'), 122.7 (C-6'), 120.6 (C-4'), 120.3 (C-5'), 112.9 (C-7'), 111.4 (C-3'), 97.5 (C-3), 91.4 (C-6), 78.8 (C-7), 72.8 (C-20), 64.8 (C-9), 54.7 (C-4), 49.6 (C-8), 42.1 (C-15), 40.4 (C-22), 37.4 (C-5), 36.7 (C-10), 34.8 (C-16), 33.7 (C-21), 20.6 (CH₃-C₁₆), 20.0 (C-12), 15.6 (C-11), 13.2 (CH₃-C₁₈)。与文献中 chaetoglobosin W 的相关数据一致^[11]。

5-(Methyl-2-butenyl)-indole-2,3-dione (8)

黄色粉末; ^1H NMR (600 MHz, CDCl₃): δ 8.85 (1H, s, H-1), 7.40 (1H, s, H-4), 7.35 (1H, d, $J = 7.8$ Hz, H-6), 6.86 (1H, d, $J = 7.8$ Hz, H-7), 5.24 (1H, m, H-2'), 3.28 (2H, overlap, H-1'), 1.75 (3H, s, H-

5'), 1.70 (3H, s, H-4'); ^{13}C NMR (150 MHz, CDCl₃): δ 183.5 (C-3), 160.0 (C-2), 147.5 (C-7a), 138.7 (C-6), 138.0 (C-5), 134.0 (C-3'), 125.3 (C-4), 121.8 (C-2'), 118.2 (C-3a), 112.4 (C-7), 33.4 (C-1'), 25.7 (C-4'), 17.8 (C-5')。与文献中 5-(methyl-2-butene)-indole-2,3-dione 的相关数据一致^[12]。

Chaetoviridin A (9) 红色粉末; $[\alpha]_D^{20} = +95^\circ$ (c 0.1, CDCl₃); HR-ESI-MS (positive mode) m/z 455.1030 [$\text{M} + \text{Na}$]⁺ (calcd for C₂₃H₂₅ClO₆Na⁺, 455.1237); ^1H NMR (600 MHz, CDCl₃): δ 8.75 (1H, s, H-1), 6.59 (1H, dd, $J = 15.6, 7.8$ Hz, H-10), 6.54 (1H, s, H-4), 6.07 (1H, d, $J = 15.6$ Hz, H-9), 3.84 (1H, m, H-5'), 3.62 (1H, m, H-4'), 2.27 (1H, m, H-11), 2.08 (1H, br, OH-5'), 1.43 (2H, m, H-12), 1.14 (3H, d, $J = 6.0$ Hz, H-6'), 1.14 (3H, d, $J = 6.0$ Hz, CH₃-4'), 1.07 (3H, d, $J = 7.2$ Hz, CH₃-11), 0.88 (3H, t, $J = 7.2$ Hz, H-13); ^{13}C NMR (150 MHz, CDCl₃): δ 201.2 (C-3'), 183.4 (C-6), 167.9 (C-1'), 162.7 (C-8), 157.1 (C-3), 151.5 (C-1), 148.0 (C-10), 139.7 (C-4a), 125.1 (C-2'), 119.8 (C-9), 110.4 (C-8a), 108.9 (C-5), 105.4 (C-4), 87.6 (C-7), 70.9 (C-5'), 51.0 (C-4'), 39.0 (C-11), 29.1 (C-12), 26.2 (CH₃-C₇), 21.4 (CH₃-C_{4'}), 19.3 (CH₃-C₁₁), 13.5 (C-6'), 11.7 (C-13)。与文献中 chaetoviridin A 的相关数据一致^[13]。

Cochliodone A (10) 白色粉末; $[\alpha]_D^{20} = -223^\circ$ (c 0.1, MeOH); HR-ESI-MS (positive mode) m/z 661.2281 [$\text{M} + \text{Na}$]⁺ (calcd for C₃₄H₃₈O₁₂Na⁺, 661.2255); ^1H NMR (600 MHz, acetone- d_6): δ 7.75 (1H, s, H-1, 1'), 3.88 (1H, m, H-12, 12'), 2.75 (1H, d, $J = 16.8$ Hz, H-4 β , 4 β'), 2.63 (1H, d, $J = 16.8$ Hz, H-4 α , 4 α'), 2.06 (3H, s, H-16, 16'), 1.90 (1H, m, H-9, 9'), 1.68 (2H, overlap, H-10, 10'/H-11, 11'), 1.58 (1H, m, H-9, 9'), 1.51 (3H, s, H-14, 14'), 1.22 (1H, m, H-11, 11'), 1.03 (3H, d, $J = 6.2$ Hz, H-13, 13'); ^{13}C NMR (150 MHz, acetone- d_6): δ 191.4 (C-6, 6'), 191.1 (C-8, 8'), 168.9 (C-15, 15'), 156.7 (C-1, 1'), 144.7 (C-4a, 4a'), 122.8 (C-5, 5'), 111.5 (C-8a, 8a'), 102.6 (C-3, 3'), 84.7 (C-7, 7'), 68.3 (C-12, 12'), 37.2 (C-4, 4'), 31.8 (C-9, 9'), 31.3 (C-11, 11'), 22.0 (C-14, 14'), 21.0 (C-13, 13'), 19.2 (C-16, 16'), 18.0 (C-10, 10')。

与文献中 cochlidone A 的相关数据一致^[14]。

3.2 体外免疫活性的测试

体外免疫活性实验表明,化合物 1~6 在低浓度情况下对小鼠脾细胞的增殖具有抑制作用,IC₅₀ 值分别为 0.21、2.8、2.3、2.2、1.7、2.7 μM(阳性 BD750, IC₅₀ = 1.0 μM)。化合物 10 无免疫抑制活性(c > 50 μM)同时化合物 1~6 对静息小鼠脾细胞存活率 IC₅₀ 值分别 0.82、7.5、2.3、6.1、4.6、6.7 μM(阳性 BD750, IC₅₀ > 50 μM),表明化合物对细胞具有较强的毒性。

4 讨论

球毛壳次生代谢物大多具有较强的生物活性,如细胞松弛素类化合物 chaetoglobosins A-G, J 对 HeLa cell 具有细胞毒活性 (IC₅₀ = 3.2 ~ 20 μg/mL)^[15]; Chaetoglobosins (A、C)对苜蓿幼苗具有植物毒素样作用^[16]; 对幽门螺旋杆菌 (*Helicobacter pylori*)、金黄色葡萄杆菌 (*Staphylococcus aureus*) 以及对植物致病菌 (*Pythium ultimum*、*Phytophthora capsici*、*Rhizoctonia solani*、*Botrytis cinerea*、*Fusarium oxysporum*) 具有一定的抑制作用^[17]。随着越来越多的体外药理活性实验模型的建立,毛壳属代谢产物更多的生物活性被人们所发现。本文采用体外检测脾细胞免疫活性旨在探索 Chaetoglobosins 类化合物在低浓度下是否具有免疫抑制活性,以开发免疫抑制新型药物。实验结果表明化合物 1~6 对脾细胞增殖具有较强的抑制作用,但同时在低浓度下对静息脾细胞具有杀伤作用,这可能与该类化合物具有较强的细胞毒性有关。

参考文献

- Zhang Q, Li HQ, Zong SC, et al. Chemical and bioactive diversities of the genus *Chaetomium* secondary metabolites. *Mini Rev Med Chem*, 2012, 12:127-148.
- Li GY, Li BG, Yang T, et al. Chaetocochins A-C, Epipolythiodioxopiperazines from *Chaetomium cochlodes*. *J Nat Prod*, 2006, 69:1374-1376.
- Xu GB, Yang T, Bao JK, et al. Isochaetomium A₂, a new bis (naphthodihydropyran-4-one) with antimicrobial and immunological activities from fungus *Chaetomium microcephalum*. *Arch Pharm Res*, 2014, 37:575-579.
- Xu GB, He G, Bai HH, et al. Indole alkaloids from *Chaetomium globosum*. *J Nat Prod*, 2015, 78:1479-1485.
- Xu GB, Li LM, Yang T, et al. Chaetoconvosins A and B, alkaloids with new skeleton from fungus *Chaetomium convolutum*. *Org Lett*, 2012, 14:6052-6055.
- Liu Y, Yang T, Li H, et al. BD750, a benzothiazole derivative, inhibits T cell proliferation by JAK3/STAT5 signal pathway. *Br J Pharmacol*, 2013, 168:632-643.
- Sekita S, Yoshihira K, Natori S. Chaetoglobosins, cytotoxic 10-(indol-3-yl)-[13] cytochalasans from *Chaetomium* spp. IV. Carbon-13 nuclear magnetic resonance spectra and their application to a biosynthetic study. *Chem Pharm Bull*, 1983, 31:490-498.
- Sekita S, Yoshihira K, Natori S, et al. Chaetoglobosins, cytotoxic 10-(indol-3-yl)-[13] cytochalasans from *Chaetomium* spp. III. Structures of chaetoglobosins C, E, F, G, and J. *Chem Pharm Bull*, 1982, 30:1629-1638.
- Iwamoto C, Yamada T, Ito Y, et al. Cytotoxic cytochalasans from a *Penicillium* species separated from a marine alga. *Tetrahedron*, 2001, 57:2997-3004.
- Cui CM, Li XM, Li CS, et al. Cytoplasmic A-G, cytochalasans from a marine-derived endophytic fungus, *Chaetomium globosum* QEN-14. *J Nat Prod*, 2010, 73:729-733.
- Zhang J, Ge HM, Jiao RH, et al. Cytotoxic chaetoglobosins from the endophyte *Chaetomium globosum*. *Planta Med*, 2010, 76:1910-1914.
- Breinholt J, Demuth H, Heide M, et al. Prenisatin (5-(3-Methyl-2-butenyl)-indole-2,3-dione): an Antifungal Isatin Derivative from *Chaetomium globosum*. *Acta Chem Scand*, 1996, 50:443-445.
- Takahashi M, Koyama K, Natori S. Four new azaphilones from *Chaetomium globosum* var. *flavoviridae*. *Chem Pharm Bull*, 1990, 38:625-628.
- Phonkerd N, Kanokmedhakul S, Kanokmedhakul K, et al. Bis-spiro-azaphilones and azaphilones from the fungi *Chaetomium cochlodes* VTh01 and *C. cochlodes* CTh05. *Tetrahedron*, 2008, 64:9636-9645.
- Sekita S, Yoshihira K, Natori S, et al. Chaetoglobosins, cytotoxic 10-(indol-3-yl)-[13] cytochalasans from *Chaetomium* spp. I. production, isolation and some cytological effects of chaetoglobosins A-J. *Chem Pharm Bull*, 1982, 30: 1609-1617.
- Ichihara A, Katayama K, Teshima H, et al. Chaetoglobosin O and other phytotoxic metabolites from *Cylindrocladium floridanum*, a causal fungus of alfalfa black rot disease. *Biosci Biotech Bioch*, 1996, 60:360-361.
- Kang J G, Kim K K, Kang K Y. Antagonism and structural identification of antifungal compound from *Chaetomium cochlodes* against phytopathogenic fungi. *Agric Chem Biotech*, 1999, 42:146-150.